Epsametostat
Epithelioid Sarcoma
Haihe Biopharma Co., Ltd.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Epithelioid Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat Epizyme, Inc. | Phase 2 | BB |
Nab-Rapamycin Sarcoma Oncology Research Center, LLC | Phase 1/2 | CCC |
Nivolumab Sarcoma Oncology Research Center, LLC | Phase 1/2 | CCC |
Atezolizumab National Cancer Institute (NCI) | Phase 1/2 | CCC |
Fludeoxyglucose National Cancer Institute (NCI) | Phase 1/2 | CCC |
View all 10 →
Same molecule, other indications
Epsametostat is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
CC
Indicative · Phase 1/2
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →